The drug can cause a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is revealed mainly in patients with mixed iris color, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by the increase in melanin content in the stromal melanocytes of the iris. Typically, brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eyes, while the entire iris or parts of it can acquire a more intense brown color.
In patients with uniformly colored eyes of blue, gray, green or brown, eye color changes after two years of use of the drug were very rare.The color change is not accompanied by any clinical symptoms or pathological changes.
After the drug was discontinued, there was no further increase in the amount of brown pigment, but the already developed color change may be irreversible.
Before starting treatment, patients should be informed about the possibility of changing eye color.
Treatment of only one eye can lead to permanent heterochromia.
In the presence of nevi or lentigo on the iris, their changes were not observed under the influence of the drug.
The drug may cause darkening, thickening and lengthening of the eyelashes and / or an increase in their number; rarely - darkening of the skin of the eyelids.
Travoprost can be used in combination with other antiglaucoma drugs for topical use. In this case, the interval between their use should be at least 5 minutes.
When wearing contact lenses before instillation of the drug, the lenses should be removed and installed back no earlier than 20 minutes after the procedure.
The bottle must be closed after each use.
Do not touch the tip of the pipette to the eye.